IMDELLTRA
GrowthBsAbBLAINJECTIONINJECTABLEPriority Review
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
6/8 — Strong
Priority Review
IMDELLTRA by Amgen is tarlatamab-dlle is a bispecific t-cell engager that binds to dll3 expressed on the surface of cells, including tumor cells, and cd3 expressed on the surface of t cells. Approved for after platinum - based chemotherapy. First approved in 2024.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMDELLTRA (tarlatamab-dlle) is a bispecific antibody therapeutic approved by the FDA in May 2024 as an injectable biologic. It represents a novel mechanism for treating hematologic malignancies, specifically designed to engage dual targets for enhanced anti-tumor activity. The drug is currently in growth lifecycle phase with significant clinical potential.
Growth
As a recently approved bispecific with growth trajectory, the brand team is likely expanding rapidly to build market presence and establish clinical uptake.
Mechanism of Action
Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle…
Indications (1)
Clinical Trials (15)
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Started Jan 2027
430 enrolled
Limited Stage Small-Cell Lung Cancer
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Started Apr 2026
160 enrolled
Small Cell Lung Cancer
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
Started Apr 2026
48 enrolled
Extensive Stage Lung Small Cell Cancer
Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
Started Jan 2026
32 enrolled
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Started Nov 2025
70 enrolled
GliomaCNS Tumor, AdultCNS Tumor, Childhood
Worked on IMDELLTRA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.